CNCure Co., Ltd. is a pioneering biotech company, founded in 2019 and funded with $10M USD to date, at the forefront of developing revolutionary bacteria-based cancer immunotherapy (BCIT) and radiopharmaceuticals. We focus on two key areas: Bacteria-based Cancer Immunotherapy and the Radiopharmaceutical Theranostics platform. BCIT is a groundbreaking cancer treatment centered on our innovative SAM (Salmonella-based Armed Microbe), which activates immunity within the tumor microenvironment, leading to strong anti-cancer effects. This therapy is currently undergoing non-human primate toxicology studies. Our radiopharmaceutical platform features [18F]DMPY2, an ultra-sensitive diagnostic agent for malignant melanoma. Following successful pre-clinical trials, [18F]DMPY2 is entering phase I/2a clinical trials, offering superior specificity over [18F]FDG and improving the detection of melanoma and metastatic lesions.